undamentalytics Newsletter
Sign in

Beam Therapeutics Inc. balance sheet

At the end of fiscal 2025, Beam Therapeutics Inc. had total assets of $1.48bn, total liabilities of $243m and shareholders' equity of $1.24bn. It held $295m in cash against $0 of debt: net cash of $295m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents37162560233436282295213
Total current assets953081,2731,0931,2118781,2691,067
Total assets1564521,4741,3421,4601,1041,4811,269
Accounts payable8679241020
Deferred revenue (current)—0861366910970
Total current liabilities291022132242061829782
Long-term debt———————100
Total debt0000000100
Total liabilities55206648608478370243316
Shareholders' equity−2012468277339817341,238953
Non-controlling interests and other (assets − liabilities − equity)302———————
Net debt (negative = net cash)−37−162−560−233−436−282−295−113
Shares outstanding7m57m68m71m82m84m102m103m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BEAM vs KPTIAGEN vs BEAMBEAM vs IBRXBEAM vs NUVB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Beam Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Beam Therapeutics Inc.